Shailender Bhatia, MD

home / authors / shailender-bhatia-md

Articles

Systemic Therapy of Metastatic Melanoma: On the Road to Cure

Shailender Bhatia, MD;Scott S. Tykodi, MD, PhD;Sylvia M. Lee, MD;John A. Thompson, MD

February 15th 2015

In this article, we summarize the systemic therapies now available for melanoma, with a focus on the recently approved agents for cutaneous melanoma; discuss important considerations in selecting a treatment from the available options; and highlight some of the promising investigational approaches for this disease.

Treatment of Metastatic Melanoma: An Overview

Shailender Bhatia, MD;Scott S. Tykodi, MD, PhD;John A. Thompson, MD

May 12th 2009

Metastatic melanoma continues to be a challenging disease to treat, with an estimated 8,420 related deaths in the United States in 2008.[1] The 10- year survival rate for patients with metastatic melanoma is less than 10%.[2] More than 3 decades after its initial approval by the US Food and Drug Administration (FDA) in 1975, dacarbazine continues to be the standard of care for most patients with this disease. High-dose interleukin-2 (HD IL-2 [Proleukin]), approved by the FDA in 1998 for metastatic melanoma, benefits a small subset of patients.